

pureScientific
technologies

PURE SCIENTIFIC TECHNOLOGIES INC.

“ Striving to make medicine work better for you...”


FORWARD LOOKING STATEMENTS

This presentation may contain forward-looking statements relating to the future performance of Pure Scientific Technologies Inc. (“PST”). Forward-looking statements, specifically those concerning future performance and the achievement of operating profitability are subject to certain risks and uncertainties, and actual results may differ materially. These risks and uncertainties include the market acceptance of PST's products and services; competition within the medical technology industry and the introduction of new entrants and/or products in PST’s markets; adverse changes in governmental regulations and policies affecting the medical technology industry; product development risks and risks of technological change; the risk of unanticipated expenses; and other risks and uncertainties all as described in PST’s business plan and offering documents. Readers are cautioned that the foregoing list of factors is not exhaustive. Although PST believes that the expectations conveyed by the forward-looking statements are reasonable based on information available to it on the date such forward-looking statements are made, no assurances can be given as to future results, levels of activity and achievements. All subsequent forward-looking statements, whether written or oral, attributable to PST or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. PST assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.

MISSION

To develop and market innovative products based on its patent-pending technologies utilizing Heliox and other gases for needle-free delivery of pharmaceuticals and CBD directly into the lungs.

CORPORATE STRATEGY




- A development stage medical device company in Irvine, CA
- New patent-pending drug delivery system for pharmaceuticals and CBD
- Initial product nearing commercialization
- User-friendly inhaler with Heliox as carrier gas
- More effective reaching target cells and distal portions of lungs
- Digitally measured dosage and pressure control
- A timely solution with broad applications for pulmonary conditions
- Experienced management team proven successful in pioneering development of brachytherapy seeds for prostate cancer
- Alliance with Nectar, Inc. brings experienced first tier design & engineering skills for medical device development & production




BENEFITS OF HELIOX

- FDA-approved breathing gas, non-toxic, non-carcinogenic with history of critical care use for decades
- Comprised of Helium (He) and Oxygen (O₂) typically in a ratio of 80:20 or 70:30
- Small helium atom makes Heliox less dense than pure oxygen and more easily absorbed by the lungs with cooling effect
- Commercially available at relatively low cost with minimal adverse effects
- An example: During acute asthma exacerbations, albuterol nebulized with Heliox (Left) leads to more significant improvement in spirometry compared with albuterol nebulized with oxygen (Right) because the lower-density Heliox improves albuterol deposition in the distal airways





Because of the very low density of helium, there is better delivery of albuterol nebulized with Heliox (Left) compared with albuterol Nebulized with oxygen (Right) in the lungs.

PRODUCT OVERVIEW



PST Heliox Inhaler

- PST Heliox Inhaler
- Potential for more efficient delivery of FDA- approved pharmaceuticals and CBD into the lungs and bloodstream
- Uses Heliox as the carrier gas in a closed loop system
- More comfortable respiratory treatment experience
- Bluetooth connection to smartphone app including:
(currently under development)
 - ✓ Secure Data Storage on dosage, flow measurement, pressure, time and date of treatment
 - ✓ Secure access by patient, caregiver and physician



EXISTING TECHNOLOGY

Heliox Therapy has been used in critical care situations historically to decrease the work of breathing, often in patients with airway obstructions or severe pulmonary distress.

Existing Heliox delivery systems are typically in the form of continuous ventilator devices that utilize constant flow of Heliox at low pressure from large tanks.

- Very complex with the patient interface and Heliox delivery system cobbled together
- Bulky and difficult to transport with large Heliox tanks
- Usage limited to hospitals and critical care facilities
- Labor intensive requiring continual oversight by medical professionals
- Requiring long periods for delivery of drugs and treatment
- Associated with high risk of hypoxia
- Expensive and wasteful of Heliox



BENEFITS OF PST'S NEW HELIOX INHALER

The **PST HELIOX INHALER** utilizes a closed loop system with **precise digital dosing controls** that coordinate delivery of the pharmaceutical compound and Heliox from a **small cartridge** in **short spurts** at the peak of inhalation.

Compared to continuous ventilator equipment devices, the PST Heliox Inhaler is:

- ✓ Simple, small footprint and transportable
- ✓ Fit for use at home, in hospitals and other medical offices and facilities
- ✓ User-friendly with patients capable of self-administering medications
- ✓ Less labor intensive
- ✓ More economical and efficient in use of Heliox gas
- ✓ Requires a much shorter period for delivery of medications, generally 4 minutes or less
- ✓ Less potential risk of hypoxia




Helios: PST Heliox Inhaler Unit

BOTTOM LINE: The PST HELIOX INHALER is conceived to be a low-cost, safe and effective, user-friendly delivery platform for CBD and pharmaceuticals

DEVELOPMENT STRATEGY

Two parallel development pathways utilizing our patent-pending technologies:



- ✓ The rapidly growing holistic cannabidiol (CBD) market, projected to hit \$16 Billion in the U.S. by 2025; inhaling is most effective way of obtaining CBD. *
 - ✓ The growing market for treatment of lung diseases using FDA-approved pharmaceuticals, including asthma, chronic bronchitis, COPD, cancer and pulmonary pandemics
- Initial thrust is the commercialization of a desktop Heliox inhaler for the CBD market. Nicknamed “HELIOS”, it is a user-friendly device for use at home or in office
 - For use with readily available CBD from hemp
 - CBD market offers great potential for near-term financial returns with minimal regulatory oversight
 - Design and development knowledge gained from the CBD devices will be leveraged into new products for FDA-approved pharmaceuticals



* New York-based investment bank [Cowen](#) & Co. released a study on the CBD (cannabidiol) market.

REGULATORY PATHWAY

- The U.S. Food and Drug Administration (“FDA”) provides regulatory oversight and approval of new pharmaceuticals and medical devices
- Heliox is already approved for human use; natural occurring holistic compounds like CBD do not generally require FDA approval
- Fusing two FDA approved products (Heliox and approved pharmaceuticals) eases approval pathway
- Potential application of FDA Section 510(k) could streamline approval process for the use of the PST Heliox inhaler
- Management team has experience with the FDA approval process, having successfully obtained approval for a number of devices in less than one year from initial filing
- Efforts underway to identify and partner with researchers in academia, industry and public and private health



ALLIANCE WITH NECTAR, INC.

- Nectar is a highly experienced interdisciplinary design, engineering and product development firm in Long Beach, CA
- 30 year history of successful development of ISO 13485 certified products with focus on medical devices
- Client base includes many industry leaders & well-known companies
- PST engaged nectar to bring its highly skilled professional team to collaborate with PST in creation, development, engineering & production of its initial products
- Assures quality control and first tier development and engineering of PST's products



ISO 13485:2016
DEVICE DEVELOPMENT

Nectar streamlines the process.

From conception to design, our multi-fledged design and development team is on hand to support you through any obstacles effortlessly.



ISO certification

Our streamlined, ISO-compliant processes help guide your product from concept to regulatory approval & commercialization with ease and speed.

30+
Years of
Experience

Commercialization delays


Our 30+ years of industry experience enable us to assist with any matter in question, including avoiding costly delay traps & inefficiencies that could derail the launch of your device or software.

1000+
Products
Delivered

Unique development approach

Our rich history of bringing 1000+ devices to the market means we can help you get your product designed and market-ready all whilst reducing unnecessary costs, like those associated with rework.

PURE SCIENTIFIC TECHNOLOGIES INC.




PHASE 1 DEVELOPMENT COMPLETED

Incorporated April 29, 2020 under the laws of Nevada, PST has now completed its Phase 1 Development Program. This Phase comprised: (i) corporate organization;(ii) assembly of management team;(iii) raise of seed financing of \$508,000, (iv)) filing of patents covering PST’s technology; and (v) completion of a working prototype of PST’s Heliox inhaler with successful laboratory testing as proof of concept.

PHASE 2 DEVELOPMENT & ENGINEERING COMPLETED

PST has now concluded its Phase 2 Development Program, comprising testing, further development and engineering, marketing studies and preparation for commercial launch of the CBD inhaler. In addition, further patents were filed covering PST’s technology, additions were made to our management team and U.S.\$2.0 Million was raised in a private placement which closed September, 2022.





18 Month Product Development Goals / Timeline

PST Heliox Inhaler - CBD Products

Target Goals (Q3 2022):

- **IPO Completed**
- Further testing and upgrades of initial inhaler product
- Dialogue with potential end users and distributors concerning use and commercialization
- Selective product introduction and demonstration
- Develop initial marketing and sales campaigns
- Preliminary planning for production and distribution

Target Goals (Q4 2022):

- Further modification testing and optimization
- Finalization of initial product for commercial release
- Limited initial production for commercial release
- Commence Marketing and sales campaigns
- Initial Sales through "soft launch"

Target Goals (Q1 2023):

- Expand marketing and sales efforts
- Increase sales of initial product
- Scale up production to meet demand
- Consider further modification to initial product based on user feedback
- Commence development of second CBD product

Target Goals (Q1 2023):

- Expand marketing and sales efforts
- Increase sales of initial product
- Scale up production to meet demand
- Further production run to incorporate changes and upgrades to initial product
- Continue development and prototype creation of second CBD product

Target Goals (Q1 2023):

- Expand marketing and sales efforts
- Increase sales of initial product
- Scale up production to meet demand
- Complete prototype of second CBD product
- Initial Production run of second CBD product

Target Goals (Q4 2023):

- Continue marketing and sales efforts
- Increase sales of initial product
- Scale up production to meet demand
- Initial marketing and sales of second CBD product
- Commercialization of second CBD product through soft launch

PST Heliox Inhaler- Pharmaceutical Products

Target Goals (Q3 2022):

- Commence dialogue with doctors, medical facilities, universities and pharma companies redevelopment of potential inhaler products for specific pharmaceutical and therapeutic applications.
- Dialogues to develop potential strategic relationships
- Conceptualize and commence development of initial product

Target Goals (Q4 2022):

- Further dialogue with doctors, medical facilities, universities and pharma companies
- Develop potential strategic relationships
- Continue Development of initial product and creation of prototype
- Commence pre-submission dialogue with FDA and retesting of initial product

Target Goals (Q1 2023):

- Complete product design and prototype of initial product
- Human testing to meet FDA requirements for safety, efficacy, dosage control, etc.
- Continue dialogue with third parties for a variety pharmaceutical and therapeutic applications
- Utilize site input to guide optimization and finalization of initial product

Target Goals (Q2 2023):

- Continue dialogue with potential partners re potential applications and new products
- Utilize input from human testing to guide optimization and finalization of initial pharma product
- Finalize initial product
- Submission for FDA approval of initial product

Target Goals (Q3 2023):

- Continue with refinement based on input from testing
- Commence conceptualization and development of additional pharma products
- Design marketing and sales campaigns for initial product
- Continue dialogue with FDA regarding initial pharma product

Target Goals (Q4 2023):

- FDA approval of initial product
- Limited initial run for product release
- Commerce initial marketing and sales campaigns
- Prepare for soft product launch in Q1 2024.
- Continue development of additional products

01

02

03

04

05

06

07

08

09

10

11

12

13

14

15

16

17

18

Oct

Nov

Dec

Jan

Feb

Mar

Apr

May

Jun

Jul

Aug

Sept

Oct

Nov

Dec

Jan


Feb

Mar

Apr

Q4
2022Q1
2023Q2
2023Q3
2023Q4
2023Q1
2024Q2
2024

Pure Scientific Technologies Team



L. MICHAEL CUTRER

CEO, PRESIDENT & DIRECTOR

Mike Cutrer is a highly accomplished executive with extensive management and technical experience in the medical device field.

He was co-founder and served for eighteen years as President, CEO and a Director of North American Scientific, Inc. ("NASI") (a NASDAQ company), a Los Angeles-based manufacturer of radioisotope products for the medical industry.

NASI was an early innovator that successfully developed and marketed brachytherapy seeds implanted for the treatment of prostate cancer.



IRWIN A. OLIAN

EXECUTIVE CHAIRMAN & DIRECTOR

Irwin Olian is a highly successful entrepreneur with a strong legal and finance background. He is a creative innovator and proven business leader.

Over the past thirty years, he has leveraged his skills in strategic business planning, management, administration, finance and law with creative thought and innovation to provide leadership to a large number of emerging companies.

He has broad experience in fields ranging from medical devices to biotechnology to high technology to entertainment to mining. His activities have included serving as the CEO or member of senior management or a director of a number of public and private companies, acting as a senior business consultant and being a strategic, early-stage investor.



PHILIP CACAYORIN

VP - TECHNOLOGY

Philip Cacayorin, serving as Vice President - Technology, brings his exceptional advanced mathematics, physics and computer engineering skills to bear on development, fabrication and marketing of our new line of products utilizing the Company's patent pending infusion technologies employing Heliox and helium as integral components of delivery systems for CBD and various pharmaceuticals directly into the lungs.




HENRY CHOW, CPA, C.A.

CHIEF FINANCIAL OFFICER

Henry has over 20 years' experience in financial and accounting matters for private and public companies, including mergers and acquisitions, IPO's and other financings as well as regulatory reporting and filings in both Canada and the U.S. He is familiar with both U.S. and Canadian accounting standards and has extensive audit experience.

Henry is a founding partner of Vancouver-based Saturna Group Chartered Professional Accountants LLP and remains active with that firm. In addition, he presently serves as CFO of California-based MedTech company Pure Scientific Technologies Inc. He is a graduate of the University of British Columbia with a Bachelor of Commerce Degree with Honours.

Pure Scientific Technologies Team



MARY BALDAUF M.D.

OUTSIDE DIRECTOR

Dr. Mary Baldauf has been practicing Medicine for 26 years. Her specialty is Pediatric Critical Care Medicine. As a physician working in an Intensive Care Unit, Dr. Baldauf uses highly developed technologies such as Nitric Oxide and Heliox in the treatment of critically ill patients. She has extensive experience in the areas of mechanical ventilation and advanced airway management.

As the founder of a medical technology company. Dr. Baldauf was granted patents for a variety of devices, including congenital heart defect models, therapeutic cushioning and devices for assisting respiration and administering fluid to patients. As a dedicated physician, Dr. Baldauf remains committed to furthering patient care through emerging technologies.

Dr. Baldauf received her undergraduate degree in Biology from Harvard University. She holds a Master of Science in Applied Human Physiology from the University of Health Sciences / Chicago Medical School. Dr. Baldauf earned her Doctor of Medicine degree at the State University of New York.




MARTIN A. URBAN M.D., MMM

OUTSIDE DIRECTOR

Dr. Martin Urban is a highly experienced radiologist with extensive management and entrepreneurial skills, whose 30-year career covers the full range of interventional radiology, computed tomography and ultrasound.

In addition to his clinical experience, Marty brings 25 years management experience in the healthcare field, including ownership and management of a full-service freestanding imaging center and private practice radiology group. He has overseen patent filing and management and has a number of patents to his credit. He presently serves as Chairman of the Dept. of Medical Imaging at two hospitals in Illinois.

Marty received his Doctor of Medicine from Northwestern University Medical School and his Master of Medical Management from the University of Southern California. He has served as a Director of PST since March 2020.




LEE DUNSTON

DIRECTOR OF CORPORATE COMMUNICATIONS

Lee has thirty-three years experience in sales and marketing, IT, management, business development and investor relations. His focus will be communicating the PST story to the investment community.

His sales, marketing and business development experience includes working with several Enterprise Resource Planning software and healthcare management technology companies as well as business development, corporate communications and investor relations with several public startup companies.

CAPITAL STRUCTURE



Current Shares Issued and Outstanding:

15,500,000

Seed Round Financing - July, 2020

\$500,000 Non-Brokered Private Placement

2,500,000 Common Shares @ U.S. \$0.20 per Share


Private Placement Financing - September 2021

\$2,000,000 Non-Brokered Private Placement

5,000,000 Common Shares @ U.S. \$0.40 per Share

One Class of Stock outstanding: Common Shares

The Company is Debt-Free



pureScientific
technologies

"Striving to make medicine work better for you..."

THANK YOU



info@purescientifictech.com



<https://www.purescientifictech.com>

Pure Scientific Technologies Inc.
Irwin Olian (213) 300-3200
Irwin@purescientifictech.com